Research ArticleOpen AccessGoogle Scholar indexed
Treatment of pulmonary coccidioidomycosis after successful hepatitis C therapy in a patient with fluconazole induced hepatotoxicity
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 1 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 2 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 3 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 4 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 5 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 6 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 7 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
- 8 Department of Medicine, Maricopa Medical Center, Phoenix, USA.
Open Journal of Gastroenterology·Volume 02 (2012)·Pages 22–27·Published 15 February 2012·DOI10.4236/ojgas.2012.21005
Copy link · social · email
Abstract
A patient with hepatitis C infection and cavitary pul- monary coccidioidomycosis is reported. Treatment of hepatitis C was associated with resolution of flucona- zole-induced hepatotoxicity. Successful treatment of he- patitis C enabled the patient to tolerate increaseing doses of fluconazole. This case highlights that hepatic toxicity of fluconazole can improve after successful treatment of hepatitis C.
KeywordsCoccidioidomycosisFluconazoleHepatotoxicity
- Ampel, N.M. (2010) New perspectives on coccidioidomycosis. Proceedings of the American Thoracic Socirty, 7,181-185. doi:10.1513/pats.200907-080AL
- Ampel, N.M. (2010) Coccidioidomycosis: A review of recent advances. Clinics in Chest Medicine, 30, 241-251. doi:10.1016/j.ccm.2009.02.004
- Grant, S.M. and Clissold, S.P. (1990) Fluconazole: A re- view of its pharmacodynamic and pharmacokinetic pro- perties,and therapeutic potential in superficial and sys- temic mycoses. Drugs, 39, 877-916. doi:10.2165/00003495-199039060-00006
- Silling, G. (2002) Fluconazole: Optimized antifungal the- rapy based on pharmacokinetics. Mycoses, 45, 39-41. doi:10.1111/j.1439-0507.2002.tb04768.x
- Song, J.C. and Deresinski S. (2005) Hepatotoxicity of an- tifungal agents. Current Opinion in Investigational Drugs, 6, 170-177.
- Gearhart, M.O. (1994) Worsening of liver func-tion with fluconazole and review of azole antifungal hepato-toxicity. The Annuals of Pharmacotherapy, 28, 1177-1181.
- Wells, C. and Lever, A.M. (1992) Dose-dependent flu- conazole hepatotoxicity proven on biopsy and rechallenge. Journal of Infection, 24, 111-112. doi:10.1016/0163-4453(92)91346-D
- Kim, H. and Bindslev-Jensen, C. (2004) Reported case of severe hepatotox-icity likely due to fluconazole and not desloratadine. Acta Haematologica, 112, 177-178. doi:10.1159/000079733
- Girois, S.B., Chapuis, F., Decul-lier, E. and Revol, B.G. (2005) Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis. European Journal of Clinical Microbiology & Infectious Disease, 24, 119-130. doi:10.1007/s10096-005-1281-2
- Wang, J.L., Chang, C.H., Young-Xu, Y. and Chan, K.A. (2010) Systematic review and meta-analysis of the toler- ability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antim- icrobial Agents and Chemotherapy, 54, 2409-2419. doi:10.1128/AAC.01657-09
- Rex, J.H., Pappas, P.G. and Karchmer, A.W. (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus ampho- tericin B as therapy for candidemia and its conse-quences in nonneutropenic subjects. Clinical Infectious Diseases, 36, 1221-1228.
- Joly, V., Bolard, J. and Yeni, P. (1992) In vitro models for studying toxicity of antifungal agents. Antimicrobial Agents and Chemotherapy, 36, 1799-1804.